

Procedure For Crystallization Of (22e)-(24r)-2-Methylene-22-Dehydro-1alpha,24,25-Trihydroxy-19-Nor-Vitamin D3

View U.S. Patent No. 11,697,635 in PDF format.

WARF: P180077US02

Inventors: Hector DeLuca, Margaret Clagett-Dame, Lori Plum, Agnieszka Flores, James Thoden, Hazel Holden

## The Invention

Disclosed are methods of purifying the compound (22E)-(24R)-2-methylene-22-dehydro- $1\alpha$ ,24,25-trihydroxy-19-nor-vitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving (22E)-(24R)-2-methylene-22-dehydro- $1\alpha$ ,24,25-trihydroxy-19-nor-vitamin D3 in a solvent comprising ethyl acetate and hexane to form a solution, allowing crystals of (22E)-(24R)-2-methylene-22-dehydro- $1\alpha$ ,24,25-trihydroxy-19-nor-vitamin D3 to form and precipitate from the solution, and recovering the crystals of (22E)-(24R)-2-methylene-22-dehydro- $1\alpha$ ,24,25-trihydroxy-19-nor-vitamin D3 from the solution.

## **Additional Information**

## For More Information About the Inventors

• Margaret Clagett-Dame

## **Tech Fields**

• Therapeutics & Vaccines: Vitamin D

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847

